What Фрагмин treats: Main Uses and Benefits

The therapeutic application of Dalteparin Sodium (Фрагмин) is used for the management and prevention of blood clot formation in high-risk patients, addressing symptoms related to systemic imbalance and acute vascular occlusion. The therapeutic uses are established across multiple clinical domains.

Treatment of Acute, Established Blood Clots

This medication is applied in clinical settings that involve acute or unstable symptom patterns, specifically in the management of confirmed Venous Thromboembolism (VTE), which includes blood clots in the legs (Deep Vein Thrombosis) and the lungs (Pulmonary Embolism). It may assist in limiting the growth or movement of existing clots, thereby providing support that helps ease the overall symptom burden associated with acute, critical symptoms such as sudden chest discomfort or significant limb swelling.

Prevention of Recurrence and Supportive Care

Фрагмин is relevant when supportive symptom management is appropriate to help prevent the formation of new blood clots in vulnerable individuals. It is commonly used across conditions presenting with acute episodes, such as following major surgery, during periods of severely restricted mobility due to acute illness, and for the extended treatment of symptomatic VTE in patients with cancer. This use contributes to improved day-to-day comfort by helping to manage the risk of recurrent symptomatic manifestations. It is also applied in the supportive management of Acute Coronary Syndromes (like Unstable Angina) where a key benefit is to support the stabilization of the acute condition.

---

“This application is relevant for managing symptomatic VTE and providing supportive prophylactic assistance in complex, high-risk patient scenarios.”

Quick Fact: Support for Vascular Strain This medication is commonly used to support general well-being in conditions that cause significant physiological strain due to vascular blockage or acute risk of blockage.

Who Can and Cannot Use Фрагмин (Dalteparin Sodium)?

The eligibility for using Dalteparin Sodium is determined by strict rules outlined in official regulatory documents, focusing on patient age, physical condition, and disease history.

Populations for Whom Use is Contraindicated

The medicine must not be used in patients with a history of confirmed or suspected immunologically-mediated Heparin-Induced Thrombocytopenia (HIT Type II). It is also prohibited for patients experiencing active major bleeding or those with known hypersensitivity to Dalteparin, other Low Molecular Weight Heparins, or pork products. Use is additionally contraindicated during epidural or spinal (neuraxial) anesthesia or spinal puncture, especially when treatment doses are administered.

Age and Condition Restrictions

Dalteparin is approved for the treatment of VTE in pediatric patients who are 1 month of age and older. Safety and effectiveness are not established for infants under 1 month. The drug must be used with caution in patients with severe renal or hepatic insufficiency, as well as in patients with uncontrolled severe hypertension. Use during pregnancy is generally permitted, provided a preservative-free formulation is used to avoid benzyl alcohol exposure.

The interaction profile for Dalteparin Sodium is defined primarily by its function as an anticoagulant, leading to official, documented concerns regarding additive effects on hemostasis and bleeding risk when combined with other agents.

Documented Pharmacodynamic Interactions

Official regulatory information emphasizes pharmacodynamic interactions that enhance the risk of hemorrhage:

• Other Anticoagulants and Platelet Inhibitors: Co-administration with oral anticoagulants (e.g., Warfarin), antiplatelet agents (e.g., Aspirin, Clopidogrel), NSAIDs, or thrombolytic agents is documented to result in an additive effect on blood clotting, significantly increasing the overall risk of bleeding.
• Potassium-Increasing Agents: Dalteparin may cause suppression of adrenal aldosterone secretion. This effect, when combined with ACE inhibitors, ARBs, or potassium-sparing diuretics, carries a risk of resulting in hyperkalemia (elevated potassium levels).

Administration Restrictions and Timing

Certain combinations are classified as a major regulatory restriction:

Classification	Interacting Agents/Procedures	Regulatory Outcome/Constraint
Contraindicated	Neuraxial Blockade (Spinal/Epidural Anesthesia)	Prohibited during high-dose Dalteparin treatment due to the documented risk of spinal/epidural hematoma.
Timing Rule	Neuraxial Procedures	Mandatory time intervals must be observed between Dalteparin injection and the procedure (or catheter removal) to mitigate bleeding risk.
Antagonism	Andexanet alfa	Documented to reduce the anti-Factor Xa activity (anticoagulant effect) of Dalteparin.

Regulatory documentation also notes that some herbal products may possess intrinsic anti-clotting properties, potentially contributing to the overall risk of hemorrhage when co-administered.

How Фрагмин Works

The action of Dalteparin Sodium (Фрагмин) is defined by its highly specific molecular intervention within the blood's intrinsic clotting mechanism.

---

Targeted Activation of Antithrombin III and Factor Xa

The primary mechanistic domain involves Dalteparin binding to and potentiating Antithrombin III (ATIII), a naturally occurring serum protein. This crucial interaction causes a conformational change in ATIII, enabling it to efficiently target and neutralize the key clotting enzyme, Coagulation Factor Xa (FXa), which is essential for initiating the final stage of coagulation.

---

Selective Disruption of the Coagulation Cascade

By preferentially blocking FXa, the drug critically inhibits the cascade that generates the final clotting enzyme, Thrombin (Factor IIa), leading to reduced fibrin formation. This molecular cascade ultimately produces the core physiological effect: restriction of thrombus propagation, leading to an antithrombotic state.

---

Biophysical Constraints and Anti-Thrombin Selectivity

The smaller size of the molecule determines its selectivity. This results in a mechanism that exhibits a higher ratio of anti-Factor Xa activity compared to its anti-Thrombin activity (approx. 2.7:1). This biophysical constraint reflects its inability to effectively bridge ATIII and Thrombin simultaneously, meaning the mechanism is primarily focused on preventing new clot factor activation rather than neutralizing factors already incorporated into an existing clot structure.

Administration Route and Technique

Dalteparin Sodium (Фрагмин) is administered primarily via subcutaneous (SC) injection into the abdominal wall or thigh. Intravenous (IV) administration is a route reserved for specific hospital settings, such as for the prevention of clotting during hemodialysis or for the management of Acute Coronary Syndromes. The medication is explicitly not to be administered by the intramuscular (IM) route. The proper technique for the subcutaneous route requires rotating the injection site and ensuring the small air bubble often present in the pre-filled syringe is not expelled before injection.

---

Official Dosing Patterns

The required dosage, measured in anti-Factor Xa International Units (IU), is determined by the specific use scenario. For general prophylaxis against blood clots, fixed doses of 2,500 IU or 5,000 IU are administered once daily. For the treatment of acute Venous Thromboembolism (VTE), regimens are typically weight-based, administered either once daily (200 IU/kg) or twice daily (100 IU/kg).

---

Frequency, Duration, and Special Protocols

The duration of use is determined by the indication. Prophylaxis often involves a short-term course of 5 to 14 days, while extended use for VTE in cancer patients typically lasts up to 6 months. Certain populations require special use protocols: dose adjustments and anti-Factor Xa level monitoring are necessary for patients with severe renal impairment and in the pediatric population. If a dose is missed, patients are instructed to contact their healthcare provider immediately and must not double the subsequent dose.

Research evidence / Overview of studies for Фрагмин

---

Evidence for Use in Treating Blood Clots in Cancer Patients

Research has explored Dalteparin for the treatment of established blood clots, known as Venous Thromboembolism (VTE), particularly in adult patients with an active malignancy. These were typically long-term randomized controlled trials (RCTs). The primary outcomes research examined were the frequency of VTE recurrence and the frequency of major bleeding events over the treatment period. Studies reported a pattern of VTE recurrence frequency in the Dalteparin group that differed from the pattern observed in the Vitamin K antagonist group during the studied six-month interval. The reported frequency of serious bleeding was generally similar. Long-term effects, beyond one year, are not fully established for every subgroup, and comparative evidence against all newer oral blood thinners remains limited.

---

Evidence for Use in Preventing Blood Clots in High-Risk Hospital Patients

Research examined the prevention of blood clots in acutely ill adults with severely restricted mobility through large, randomized, placebo-controlled trials. These studies monitored the incidence of objectively confirmed VTE. Data show patterns related to a difference in the reported frequency of VTE events between the observed groups and the placebo groups. The necessity of extending clot prevention beyond the acute recovery phase is not conclusively supported, as follow-up durations were limited in this context. Evidence derived from settings with varying symptom burdens, such as for critically ill patients with severe kidney problems, often comes from smaller analyses.

---

Research Gaps and Areas of Uncertainty

Areas of uncertainty remain regarding the evidence quality across studies. For instance, in pediatric populations, the research relies heavily on monitoring a surrogate biomarker (anti-Factor Xa activity) instead of comprehensive, long-term clinical events, meaning certainty remains low regarding sustained clinical effects. For adults, comparative evidence is lacking against all currently available treatment classes for certain conditions. Research is ongoing to better characterize the long-term impact on patient-reported outcomes.

Common questions about Фрагмин (FAQ)

---

Q: Is it safe to get pregnant while taking Dalteparin?

Regulatory documents state that Dalteparin is indicated for use during pregnancy only if the potential benefit justifies the potential risk. The official product information specifically notes that preservative-free formulations are required during pregnancy to avoid the risk associated with benzyl alcohol, which may be harmful to a developing fetus or neonate.

---

Q: Is there a difference in how Dalteparin is given for people on hemodialysis compared to those being treated for a heart attack?

Yes, official dosing information confirms differences in the administration route for these two scenarios. For patients undergoing hemodialysis, Dalteparin is typically administered directly into the vein (intravenous or IV). In contrast, for treating conditions like Unstable Coronary Artery Disease (a type of heart attack), the medication is generally given as an injection under the skin (subcutaneous or SC).

---

Q: Can Dalteparin cause fever or chills?

The official product information does not commonly list fever or chills among the frequent adverse events. However, these symptoms are sometimes mentioned in the context of rare, serious allergic or hypersensitivity reactions, which are documented as potential adverse events for this medication.

---

Q: How quickly does Fragmin start to work after injection?

The onset of the drug’s biological effect (measured by anti-Factor Xa activity) is generally observed shortly after injection. Pharmacokinetic data indicates the mean terminal half-life of Dalteparin following subcutaneous injection is approximately 3.5 to 4 hours.

Storage and Disposal of Fragmin (Dalteparin Sodium)

Fragmin must be stored at controlled room temperature, specifically between 68°F and 77°F (20°C and 25°C). It is critical to not freeze the medication and to protect it from excessive heat and moisture. Storage must be out of the reach and sight of children.

In-Use Stability

Product Type	Stability Rule
Multiple-dose Vials	Discard 14 days after the first entry.
Single-dose Syringes	For one-time use only; discard immediately after use.

Disposal Requirements

All used needles and syringes (sharps) must be placed in an FDA-cleared, puncture-resistant sharps disposal container. Sharps must not be disposed of in household trash and must be handled according to local, state, or regional regulations. Unused medicine should be disposed of via a drug take-back program.